CNS Pharmaceuticals CFO granted 9,500 RSUs

O'Loughlin Steve reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

O'Loughlin Steve reported acquisition or exercise transactions in this Form 4 filing.

CNS Pharmaceuticals, Inc. reported that Chief Financial Officer Steve O'Loughlin received a grant of 9,500 restricted stock units on March 2, 2026. Each restricted stock unit represents a contingent right to receive one share of the company’s common stock, issued in connection with his employment.

The award vests over time: 25% on the six-month anniversary of the grant date, another 25% on the twelve-month anniversary, and the remaining 50% in twelve quarterly installments thereafter, subject to his continued employment on each vesting date. Following this grant, he holds 9,500 restricted stock units directly.

Insider Trade Summary

Grant/Award: 9,500 shares

Grant/Award 1 txn

Insider O'Loughlin Steve

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	9,500	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 9,500 contracts (Direct)

Footnotes (3)

1. F1. Each restricted stock unit represents a contingent right to receive one share of Company common stock.
2. F2. The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.
3. F3. Issued in connection with the reporting person's employment with the Company.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did CNSP report about its CFO in this Form 4 filing?

CNS Pharmaceuticals (CNSP) reported that Chief Financial Officer Steve O'Loughlin received 9,500 restricted stock units on March 2, 2026. These equity awards are tied to his employment and vest over time if he remains with the company.

How many restricted stock units did the CNSP CFO receive?

The CNS Pharmaceuticals (CNSP) Chief Financial Officer received 9,500 restricted stock units. After this grant, his reported direct holdings total 9,500 restricted stock units, each representing a contingent right to receive one share of company common stock upon vesting and settlement.

What does each CNSP restricted stock unit represent in this grant?

Each restricted stock unit granted to the CNS Pharmaceuticals (CNSP) CFO represents a contingent right to receive one share of the company’s common stock. Actual share delivery depends on the units vesting under the specified schedule and the executive remaining employed through each vesting date.

What is the vesting schedule for the CNSP CFO’s 9,500 RSUs?

The CNS Pharmaceuticals (CNSP) CFO’s 9,500 restricted stock units vest 25% six months after the grant date, another 25% twelve months after the grant date, and the remaining 50% in twelve quarterly installments, all conditioned on his continued employment at each vesting date.

Why were these CNSP restricted stock units issued to the CFO?

The restricted stock units were issued in connection with the CNS Pharmaceuticals (CNSP) CFO’s employment. This type of equity compensation is commonly used to align an executive’s interests with shareholders by delivering company stock over time as service-based vesting conditions are met.

Are the CNSP CFO’s restricted stock units immediately vested or subject to conditions?

The CNS Pharmaceuticals (CNSP) CFO’s restricted stock units are subject to a multi-stage vesting schedule and are not fully vested immediately. Vesting occurs at six and twelve months, then through twelve quarterly installments, contingent on his continued employment on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 05:01 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Loughlin Steve

(Last) (First) (Middle)

C/O CNS PHARMACEUTICALS, INC.

100 WEST LOOP SOUTH, SUITE 900

(Street)

HOUSTON TX 77027

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CNS Pharmaceuticals, Inc. [ CNSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	03/02/2026		A		9,500		(2)	03/02/2036	Common Stock	9,500	(3)	9,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Company common stock.

2. The restricted stock units set forth in the table vest as follows: 25% on the six-month anniversary of the transaction date, 25% on the twelve-month anniversary of the transaction date, and the remaining 50% in twelve quarterly installments thereafter, subject to the reporting person's continued employment on each vesting date.

3. Issued in connection with the reporting person's employment with the Company.

	/s/ Christopher Downs, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.